Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Gianluca Spitaleri, Filippo de Marinis, Niki Karachaliou, Chiara Catania, Antonio Passaro, Chiara Lazzari, Alessia Pochesci, Rafael Rosell
Publikováno v:
OncoTargets and therapy
The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung can
Autor:
Lorenzo Preda, Cristina Noberasco, Chiara Lazzari, Tommaso De Pas, Francesca Toffalorio, Fabio Conforti, Massimo Barberis, Gianluca Spitaleri, Filippo de Marinis, Chiara Catania, Michela Manzotti
Publikováno v:
OncoTargets and therapy
We report the case of a man with an advanced nonkeratinizing squamous cell thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. This aberration is rare and has never been described previously in patients with thymic cancers. It has been
Autor:
Filippo de Marinis, Cristina Noberasco, Roberto Biffi, Chiara Catania, Chiara Lazzari, Massimo Barberis, Francesca Toffalorio, Gianluca Spitaleri, Caterina Fumagalli, Tommaso De Pas
Publikováno v:
OncoTargets and therapy
The development of gastrointestinal stromal tumors (GISTs) is largely driven by mutations in the KIT and PDGFRα genes. Imatinib mesylate is an oral small molecular tyrosine kinase inhibitor that mainly targets abl, c-KIT, and PDGFRα. Imatinib achie